Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR107 in healthy male subjects
NCT03067363Phase 1Terminated
- Sponsor
- Alan Richardson
- Start
- Feb 2017
- Primary completion
- Mar 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MOR107 in idiopathic pulmonary fibrosis (IPF) and diabetic nephropathy (DN), sponsored by Alan Richardson. Started Feb 2017; status: terminated.
02
Drugs
MOR107
03
Conditions
idiopathic pulmonary fibrosis (IPF)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT03067363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03067363.